Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma

Journal of Immunotherapy

Volumn 38, Issue 1, 2015, Pages 37-39

  Chan, Matthew M K ^a,b,c   Kefford, Richard F ^a,b,c,d   Carlino, Matteo ^a,b,c,d   Clements, Arthur ^a,c   Manolios, Nicholas ^a,c  

^a WESTMEAD HOSPITAL   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Anti PD1 antibody; Arthritis; Immunotherapy; Melanoma; PD1

Indexed keywords

DOUBLE STRANDED DNA; HYDROXYCHLOROQUINE; NAPROXEN; OXYCODONE; PARACETAMOL; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANKLE ARTHRITIS; ARTHRITIS; ARTICLE; AXILLARY LYMPH NODE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYST RUPTURE; ECHOGRAPHY; FEMALE; HUMAN; KNEE ARTHRITIS; LYMPHADENOPATHY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POPLITEAL CYST; TENOSYNOVITIS; CHEMICALLY INDUCED; MELANOMA;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ARTHRITIS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; TENOSYNOVITIS;

EID: 84917708727     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000060     Document Type: Article

References (10)

1. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-144.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
3. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
4. Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945-954.
5. Butte MJ, Pena-Cruz V, Kim MJ, et al. Interaction of human PD-L1 and B7-1. Mol Immunol. 2008;45:3567-3572.
6. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574:37-41.
7. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
8. Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119:1675-1682.
9. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198:63-69.
10. Mozaffarian N, Wiedeman AE, Stevens AM. Active systemic lupus erythematosus is associated with failure of antigenpresenting cells to express programmed death ligand-1. Rheumatology (Oxford). 2008;47:1335-1341.